Optimal osmotic range for a drug-containing solution suitable for lymphatic delivery

2:

• The preparation according to claim 1, wherein the osmotic pressure of the liquid ranges from 900 to 2,700 kPa.

3:

• The preparation according to claim 1, wherein the osmotic pressure of the liquid ranges from 700 to 2,400 kPa.

4:

• The preparation according to claim 1, wherein the osmotic pressure of the liquid ranges from 950 to 2,000 kPa.

5:

• The preparation according to claim 1, wherein a viscosity of the liquid ranges from 0.5 to 20 mPa·s.

6:

• The preparation according to claim 1, wherein a viscosity of the liquid ranges from 1.0 to 15 mPa·s.

7:

• The preparation according to claim 1, wherein the preparation further comprises a nonionic surfactant.

8:

• The preparation according to claim 7, wherein the nonionic surfactant is a polyoxyethylene sorbitan fatty acid ester.

9:

• The preparation according to claim 8, wherein the polyoxyethylene sorbitan fatty acid ester is polyoxyethylene sorbitan oleate.

10:

• The preparation according to claim 1, wherein the drug is a pharmaceutically active substance, a nucleic acid molecule container or a cultured cell.

11:

• The preparation according to claim 1, wherein the drug is an anticancer drug.

12:

• A lymphatic drug delivery method, comprising delivering a drug to a target with the intralymphatic liquid preparation according to claim 1.

13:

• The method according to claim 12, wherein the drug is a pharmaceutically active substance, a nucleic acid molecule container or a cultured cell.

14:

• The method according to claim 12, wherein the drug is an anticancer drug.